March 27, 2000 05:00am
New Therapeutics Inject Vigor into HIV Testing Market
Source: Frost & Sullivan Clinical Diagnostics
by: Company Press Release
(MOUNTAIN VIEW, CA) -- HIV disease management and clinical pathology are seeing a revolution with the introduction of therapeutic practices for managing patients' health.
In addition to viral load and CD4 cell monitoring, viral genotyping is emerging as a vital tool in improving the clinical outcome of HIV patients. This has initiated a boom in the $265.6 million market for HIV diagnostics and monitoring.
In their new strategic research ``U.S. HIV Diagnostics and Monitoring Markets,'' Frost & Sullivan (www.frost.com) forecasts a compounded annual growth rate of 12.6 percent through 2005.
According to Frost & Sullivan Clinical Diagnostics Analyst John Keefe, decentralization of HIV viral load monitoring and its extensive usage in hospitals and reference laboratories are major market drivers. The HIV genotyping market, with its immense revenue potential, is expected to follow suit once FDA approval for a genotyping assay comes through. While a high degree of public awareness promotes screening, the increasing AIDS patient population and their improving life expectancies ensure continued demand for monitoring.
Since many patients never return for test results, the Center for Disease Control recommends that all public testing facilities use rapid HIV tests, which yield results on-site in less than two hours. As physicians begin to perform these new tests in their offices instead of a laboratory, those firms that have their market share focused on public testing facilities may face challenges in the future.
New tests and treatments are also changing the market, opening the doors for small companies with niche market products. ``Though few dominant players enjoy massive shares in individual market segments, new diagnosis and treatment strategies are forecast to expand certain markets that could tilt the balance toward smaller players,'' Keefe notes.
This biotechnology and pharmaceutical diagnostics industry research has integrated the market engineering consulting philosophy into the entire research process. Critical phases of this research included: identification of industry challenges, market engineering measurements, strategic recommendations, planning and market monitoring. All of the vital elements of this system help the market participants navigate successfully through the U.S. HIV diagnostics and monitoring market.
Companies participating within this industry include: Abbott Diagnostics Division, Bayer Diagnostics, Beckman Coulter, Becton Dickinson, Intracel Corporation, Organon Teknika, PE Biosystems, Roche Diagnostics and Visible Genetics. Other related companies are: Affymetrix Inc., HYSEQ Inc. and Qiagen Inc.
Frost & Sullivan, which is headquartered in Mountain View, Calif., is a global leader in international marketing consulting and training. Frost & Sullivan monitors the diagnostics industry for market trends, market measurements and strategies. This ongoing research is included in the Frost & Sullivan Online ``Clinical Diagnostics & Drug Discovery Technologies Custom Subscription,'' and is utilized to support industry participants with customized consulting needs. Free executive summaries of all Frost & Sullivan research are available to the press through our media relations department.
U.S. HIV Diagnostics and Monitoring Markets